[1. Roth, Christian Hartmann et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology 2016; 18(11), 1529–1537.]Search in Google Scholar
[2. Vincent T. DeVita Jr. MD, Theodore S. Lawrence PhD, MD, Steven A. Rosenberg MD, PhD: Principles & Practice of Oncology,10th edition, Wolters Kluwer Health, 2015.]Search in Google Scholar
[3. David N. Louis et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System.2016; 131:803–820.10.1007/s00401-016-1545-1]Search in Google Scholar
[4. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379(9830):1984-1996.10.1016/S0140-6736(11)61346-9]Search in Google Scholar
[5. Tortosa A, Viñolas N, Villà S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003;97(4): 1063-1071.10.1002/cncr.11120]Search in Google Scholar
[6. Dolecek TA et al. Primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012; 14:v1–v49.10.1093/neuonc/nos218]Search in Google Scholar
[7. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA. Prognostic factors for anaplastic astrocytomas. J Neurooncol. 2007;81(3):295-303.10.1007/s11060-006-9232-z]Search in Google Scholar
[8. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110(1):156-162.10.3171/2008.4.17536]Search in Google Scholar
[9. Rogne SG et al. Anaplastic astrocytomas: survival and prognostic factors in a surgical series. Acta Neurochir. 2014; 156(6):1053-61.10.1007/s00701-014-2053-5]Search in Google Scholar
[10. Prados MD, Gutin PH, Phillips TL, et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys. 1992; 23(1):3-8.10.1016/0360-3016(92)90537-R]Search in Google Scholar
[11. Liang BC, Thornton AF, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg. 1991;75(4):559-563.10.3171/jns.1991.75.4.05591653309]Search in Google Scholar
[12. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol. 2002;58(3):203-215.10.1023/A:1016261900413]Search in Google Scholar
[13. Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol. 2012;14(1):109-116.10.1093/neuonc/nor185324599822039037]Search in Google Scholar
[14. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB- 1), PCNA, and S-phase fraction using archival paraffinembedded samples. J Pathol. 1994;174(4):275-282.10.1002/path.17117404077884589]Search in Google Scholar
[15. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120 (6):707-718.10.1007/s00401-010-0781-z21088844]Search in Google Scholar
[16. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93(16):1246-125610.1093/jnci/93.16.124611504770]Search in Google Scholar
[17. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.10.1200/JCO.2012.43.2674373201223071247]Search in Google Scholar
[18. Maria Teresa Solomon et al. Nimotuzumab in combination with radiotherapy in high grade glioma patients, Cancer Biology & Therapy. (2014); 15:5, 504–509.10.4161/cbt.28021402607224521695]Search in Google Scholar
[19. Ohgaki H, Kleihues P Genetic pathways to primary and secondary glioblastoma.Am J Pathol. (2007). 170(5):1445-53.10.2353/ajpath.2007.070011185494017456751]Search in Google Scholar
[20. Valiyaveettil D, Malik M, Joseph D, Ahmed SF, Kothwal SA. Prognostic factors and outcomes in anaplastic gliomas: An institutional experience. South Asian J Cancer. 2018;7(1):1-4.10.4103/sajc.sajc_55_17586508529600221]Search in Google Scholar
[21. Reuss DE, Mamatjan Y, Schrimpf D,Capper D, Hovestadt V, Kratz A, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. (2015) 129(6):867-73.10.1007/s00401-015-1438-8450003925962792]Search in Google Scholar